Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$164.86M$164.86M+162.1% vs Q3 2024 Net Income$25.71M$25.71MN/M vs Q3 2024 EPS Diluted$0.28$0.28N/M vs Q3 2024 Operating Income$24,931,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$14,177,000N/M Margins · derivedOperating margin15.1%+104.4 pt vs Q3 2024
Net margin15.6%+102.7 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end